Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

benzinga.com/markets/large-cap/25/06/45912248/novartis-fabhalta-delivers-hemoglobin-gains-reduces-fatigue-in-patients-with-rare-blood-disorde

Novartis AG (NYSE:NVS) on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5…

This story appeared on benzinga.com, 2025-06-12 18:25:16.
The Entire Business World on a Single Page. Free to Use →